Search
Ceftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of
Tacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalIt reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. … Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection.
Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland.
N-Acetylglucosamine
go.drugbank.com/drugs/DB00141ApprovedInvestigationalNutraceuticalThe N-acetyl derivative of glucosamine.
Mixtures: Cheon Shim Bo YunSynonyms: N-Acetylchitosamine, N-AcetylglucosaminePibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalMavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940]. … patients with moderate to severe kidney disease and those who are on dialysis [L940].
Donislecel
go.drugbank.com/drugs/DB17961Approved, by not relying on exogenous and intentional insulin administration to control blood glucose. … [L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196]
Olsalazine
go.drugbank.com/drugs/DB01250Approved[A257063] It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. … [A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSSelexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalSelexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary
Crotalus adamanteus antivenin
go.drugbank.com/drugs/DB13893ApprovedThe final purified antivenin product is obtained by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques. … It is intravenously administered to limit systemic toxicity [FDA label].
Temozolomide
go.drugbank.com/drugs/DB00853ApprovedInvestigational[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow … [A229853, A229923] Temozomolide as an adjunct to radiotherapy followed by maintenance dosing remains the standard of care for both Glioblastoma and refractory anaplastic astrocytoma.